Floatz logo

Inalimarev

Pancreatic Acinar Cell Carcinoma

National Cancer Institute (NCI)vaccinePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Pancreatic Acinar Cell Carcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Yale University
Phase 2BBB
Eloxatin
Yale University
Phase 2BBB
Irinotecan
Artios Pharma Ltd
Phase 2BB
Metformin
Case Comprehensive Cancer Center
Phase 2BB
Carboplatin
National Cancer Institute (NCI)
Phase 2B

View all 34 →

Same molecule, other indications

Inalimarev is also rated in:

metastatic malignant neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
48 / 100
View asset →
malignant pancreatic neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →